AVI BioPharma 2006 News Archive

December

AVI BioPharma and Ercole Biotech Announce Cross-License and Drug Discovery Collaboration for Alternative Splicing Therapeutics December 20, 2006, Portland, Oregon and Research Triangle Park, N.C.
AVI BioPharma Announces Clinical Development Initiative For Muscular Dystrophy December 7, 2006, Portland, Oregon
AVI BioPharma Awarded $28 Million Biodefense Research Contract by Department of Defense/DTRA December 4, 2006, Portland, Oregon

November

2006 Third Quarter Financial Results Conference Call Transcript November 27, 2006, Portland, Oregon
AVI BioPharma Announces Positive Clinical Trial Results Delivering NeuGene Antisense Drugs to the Central Nervous System November 10, 2006, Portland, Oregon
AVI BioPharma Reports Third Quarter Financial Results November 8, 2006, Portland, Oregon
AVI BioPharma to Present Strategic Overview at Two Investor Conferences November 6, 2006, Portland, Oregon
AVI BioPharma Announces 2006 Third Quarter Financial Results Conference Call November 1, 2006, Portland, Oregon

October

AVI BioPharma Discusses Phase II Cardiovascular Clinical Study October 31, 2006, Portland, Oregon
AVI BioPharma Publishes Preclinical Data Showing NeuGene Antisense Inhibition of Multiple Strains of Influenza A Virus October 27, 2006, Portland, Oregon
AVI BioPharma Presents Successful Trial Results Using NeuGene Antisense to Alter Drug Metabolism in Humans October 19, 2006, Portland, Oregon
AVI BioPharma Initiates NeuGene Antisense Clinical Program in Coronary Artery Bypass Grafting October 18, 2006, Portland, Oregon
AVI BioPharma Reports Results on Hepatitis C Virus Clinical Trial October 04, 2006, Portland, Oregon

September

AVI BioPharma Presents Positive Preclinical Data Evaluating NeuGene Antisense Compounds Against Influenza A Virus and the E. coli Bacteria September 29, 2006, Portland, Oregon
AVI BioPharma to Present at UBS Global Life Sciences Conference September 27, 2006, Portland, Oregon

August

2006 Second Quarter Financial Results Conference Call Transcript August 10, 2006, Portland, Oregon
AVI BioPharma Announces Publication of Positive Results From New Class of Antibiotics Using NeuGene Antisense Technology August 9, 2006, Portland, Oregon
AVI BioPharma Reports Second Quarter Financial Results August 8, 2006, Portland, Oregon
AVI BioPharma Provides Cardiovascular Program Update August 3, 2006, Portland, Oregon
AVI BioPharma Announces 2006 Second Quarter Financial Results Conference Call August 1, 2006, Portland, Oregon

July

AVI BioPharma Announces Hepatitis C Virus Clinical Study Modification July 20, 2006, Portland, Oregon

June

AVI BioPharma to Present at Rodman & Renshaw 3rd Annual Security, Biodefense & Connectivity Investor Conference June 19, 2006, Portland, Oregon
AVI BioPharma Presents Preclinical Results Preventing and Treating Diabetes Using Its ESPRIT Exon Skipping Technology June 5, 2006, Portland, Oregon

May

AVI BioPharma Receives Notice of Allowance for a Patent Application Covering the Use of NeuGene Antisense Technology for the Development of a New Class of Antibiotics May 24, 2006, Portland, Oregon
AVI BioPharma to Present at Rodman & Renshaw 3rd Annual Global Healthcare Conference May 11, 2006, Portland, Oregon
First Quarter 2006 Financial Results Conference Call Transcript May 10, 2006, Portland, Oregon
AVI BioPharma Presents Initial Results on Hepatitis C Virus Clinical Trial at the International Conference on Antiviral Research Annual Meeting May 10, 2006, Portland, Oregon
AVI BioPharma Reports Preclinical Data Against Multiple Strains of Influenza May 9, 2006, Portland, Oregon
AVI BioPharma Announces First Quarter Financial Results May 5, 2006, Portland, Oregon

April

AVI BioPharma Announces 2006 First Quarter Financial Results Conference Call April 28, 2006, Portland, Oregon
AVI BioPharma to Present at UBS Global Specialty Pharmaceuticals Conference April 21, 2006, Portland, Oregon
AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial Status April 20, 2006, Portland, Oregon

March

AVI BioPharma Reports Successful Inhibition of Multiple Subtypes of Influenza A Using NeuGene Antisense Therapeutic March 30, 2006, Portland, Oregon
AVI BioPharma and Cook Group Enter Into License Agreement to Develop NeuGene Drugs for Vascular Diseases March 13, 2006, Portland, Oregon
AVI BioPharma Incorporated 2005 Fourth Quarter and Year–End Financial Results Conference Call Transcript March 10, 2006, Portland, Oregon
AVI BioPharma Announces 2005 Fourth Quarter and Full Year Financial Results March 8, 2006, Portland, Oregon
AVI BioPharma Successful Ebola Study Results Highlighted in Nature Reviews Drug Discovery March 7, 2006, Portland, Oregon
AVI BioPharma Announces 2005 Fourth Quarter and Year End Financial Results Conference Call March 1, 2006, Portland, Oregon

February

Successful Muscular Dystrophy Treatment Results Using AVI BioPharma Technology Published in Nature Medicine February 9, 2006, Portland, Oregon

January

AVI BioPharma Announces Hepatitis C Virus License Agreement With Chiron January 27, 2006, Portland, Oregon
AVI BioPharma Reports Confirmation of Efficacy Against Influenza Strains January 20, 2006, Portland, Oregon
AVI BioPharma’s NeuGene Shows Success Against Deadly Ebola Virus January 13, 2006, Portland, Oregon
AVI BioPharma Reports Favorable Safety and Pharmacokinetic Data From Its Clinical Trial Targeting Hepatitis C Virus January 10, 2006, Portland, Oregon
Increased Defense–Related Funding of AVI BioPharma Approved January 4, 2006, Portland, Oregon

About AVI BioPharma

Technology

Communication